Participants received @ initial monthly ranibizumab @ mg injections ( day @ to month @ ) , followed by individualized best-corrected visual acuity ( BCVA ) and optical coherence tomography-guided re-treatment with monthly ( months @-@ ) and subsequent bimonthly follow-up ( months @-@ ) .